Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Record-high Life Expectancy Reported for Both Sexes in 2001
August 19, 2002
- FPMAJ to Present Industry's Proposal Regarding Application of New PAL
August 19, 2002
- Drugs to Be Included in 20th Quality Reevaluation Announced
August 19, 2002
- Fujisawa Invests US$8 Mil. in Sucampo
August 19, 2002
- REGULATORY NEWS IN BRIEF
August 19, 2002
- stay.safe balance to Enhance QOL of Dialysis Patients: Mr van Hest of Fresenius
August 5, 2002
- NEW PRODUCTS
August 5, 2002
- Sankyo to Tie Up with LifeSpan Biosciences on Pharmacogenomics
August 5, 2002
- Dainippon Licenses Reagent to Determine Blood Zonisamide to Opus of the US
August 5, 2002
- Molecular Targeted Drugs for Liver Cancer: Banyu, IMSUT
August 5, 2002
- Wholesalers May Be Engaged in Disease Management: Mr Bessho of Suzuken
August 5, 2002
- Aderans to Start Research on Hair Regeneration Therapy in US
August 5, 2002
- Pharmaceutical Affairs Law Amendment Passes Diet
August 5, 2002
- Prulifloxacin Recommended for Approval
August 5, 2002
- Pharmaco-business Innovation Chair to Be Established at Univ. of Tokyo
August 5, 2002
- Views of the JPMA President Regarding the Amendment of the Pharmaceutical Affairs Law
August 5, 2002
- Dear-Doctor Letter Issued for Ticlopidine
August 5, 2002
- Risk Management, Cost-effectiveness Analysis Stressed: CMIC Seminar
August 5, 2002
- Council Insists on Entry of Private Corporations into Medical Facilities
August 5, 2002
- Serious ADRs Reported for 3 Products Including Edaravone
August 5, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…